Retinoprotective Effects of TAT-Bound Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase Activating Polypeptide

Tamas Atlasz, D. Werling, S. Song, E. Szabo, A. Vaczy, P. Kovari, A. Tamás, D. Reglodi, Rongjie Yu

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP) belong to the same peptide family and exert a variety of biological functions. Both PACAP and VIP have protective effects in several tissues. While PACAP is known to be a stronger retinoprotective peptide, VIP has very potent anti-inflammatory effects. The need for a non-invasive therapeutic approach has emerged and PACAP has been shown to be retinoprotective when administered in the form of eye drops as well. The cell penetrating peptide TAT is composed of 11 amino acids and tagging of TAT at the C-terminus of neuropeptides PACAP/VIP can enhance the traversing ability of the peptides through the biological barriers. We hypothesized that TAT-bound PACAP and VIP could be more effective in exerting retinoprotective effects when given in eye drops, by increasing the traversing efficacy and enhancing the activation of the PAC1 receptor. Rats were subjected to bilateral carotid artery occlusion (BCCAO), and retinas were processed for histological analysis 14 days later. The efficiency of the TAT-bound peptides to reach the retina was assessed as well as their cAMP increasing ability. Our present study provides evidence, for the first time, that topically administered PACAP and VIP derivatives (PACAP-TAT and VIP-TAT) attenuate ischemic retinal degeneration via the PAC1 receptor presumably due to a multifactorial protective mechanism.

Original languageEnglish
JournalJournal of Molecular Neuroscience
DOIs
Publication statusAccepted/In press - Jan 1 2018

Fingerprint

Pituitary Adenylate Cyclase-Activating Polypeptide
Vasoactive Intestinal Peptide
Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I
Peptides
Ophthalmic Solutions
Retina
Cell-Penetrating Peptides
Retinal Degeneration
Neuropeptides
Carotid Arteries
Anti-Inflammatory Agents
Amino Acids

Keywords

  • Bio-barriers
  • Eye drops
  • Retinal protection
  • TAT

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience

Cite this

Retinoprotective Effects of TAT-Bound Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase Activating Polypeptide. / Atlasz, Tamas; Werling, D.; Song, S.; Szabo, E.; Vaczy, A.; Kovari, P.; Tamás, A.; Reglodi, D.; Yu, Rongjie.

In: Journal of Molecular Neuroscience, 01.01.2018.

Research output: Contribution to journalArticle

@article{7df8dd21782d41239a55ad8edc350548,
title = "Retinoprotective Effects of TAT-Bound Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase Activating Polypeptide",
abstract = "Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP) belong to the same peptide family and exert a variety of biological functions. Both PACAP and VIP have protective effects in several tissues. While PACAP is known to be a stronger retinoprotective peptide, VIP has very potent anti-inflammatory effects. The need for a non-invasive therapeutic approach has emerged and PACAP has been shown to be retinoprotective when administered in the form of eye drops as well. The cell penetrating peptide TAT is composed of 11 amino acids and tagging of TAT at the C-terminus of neuropeptides PACAP/VIP can enhance the traversing ability of the peptides through the biological barriers. We hypothesized that TAT-bound PACAP and VIP could be more effective in exerting retinoprotective effects when given in eye drops, by increasing the traversing efficacy and enhancing the activation of the PAC1 receptor. Rats were subjected to bilateral carotid artery occlusion (BCCAO), and retinas were processed for histological analysis 14 days later. The efficiency of the TAT-bound peptides to reach the retina was assessed as well as their cAMP increasing ability. Our present study provides evidence, for the first time, that topically administered PACAP and VIP derivatives (PACAP-TAT and VIP-TAT) attenuate ischemic retinal degeneration via the PAC1 receptor presumably due to a multifactorial protective mechanism.",
keywords = "Bio-barriers, Eye drops, Retinal protection, TAT",
author = "Tamas Atlasz and D. Werling and S. Song and E. Szabo and A. Vaczy and P. Kovari and A. Tam{\'a}s and D. Reglodi and Rongjie Yu",
year = "2018",
month = "1",
day = "1",
doi = "10.1007/s12031-018-1229-5",
language = "English",
journal = "Journal of Molecular Neuroscience",
issn = "0895-8696",
publisher = "Humana Press",

}

TY - JOUR

T1 - Retinoprotective Effects of TAT-Bound Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase Activating Polypeptide

AU - Atlasz, Tamas

AU - Werling, D.

AU - Song, S.

AU - Szabo, E.

AU - Vaczy, A.

AU - Kovari, P.

AU - Tamás, A.

AU - Reglodi, D.

AU - Yu, Rongjie

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP) belong to the same peptide family and exert a variety of biological functions. Both PACAP and VIP have protective effects in several tissues. While PACAP is known to be a stronger retinoprotective peptide, VIP has very potent anti-inflammatory effects. The need for a non-invasive therapeutic approach has emerged and PACAP has been shown to be retinoprotective when administered in the form of eye drops as well. The cell penetrating peptide TAT is composed of 11 amino acids and tagging of TAT at the C-terminus of neuropeptides PACAP/VIP can enhance the traversing ability of the peptides through the biological barriers. We hypothesized that TAT-bound PACAP and VIP could be more effective in exerting retinoprotective effects when given in eye drops, by increasing the traversing efficacy and enhancing the activation of the PAC1 receptor. Rats were subjected to bilateral carotid artery occlusion (BCCAO), and retinas were processed for histological analysis 14 days later. The efficiency of the TAT-bound peptides to reach the retina was assessed as well as their cAMP increasing ability. Our present study provides evidence, for the first time, that topically administered PACAP and VIP derivatives (PACAP-TAT and VIP-TAT) attenuate ischemic retinal degeneration via the PAC1 receptor presumably due to a multifactorial protective mechanism.

AB - Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP) belong to the same peptide family and exert a variety of biological functions. Both PACAP and VIP have protective effects in several tissues. While PACAP is known to be a stronger retinoprotective peptide, VIP has very potent anti-inflammatory effects. The need for a non-invasive therapeutic approach has emerged and PACAP has been shown to be retinoprotective when administered in the form of eye drops as well. The cell penetrating peptide TAT is composed of 11 amino acids and tagging of TAT at the C-terminus of neuropeptides PACAP/VIP can enhance the traversing ability of the peptides through the biological barriers. We hypothesized that TAT-bound PACAP and VIP could be more effective in exerting retinoprotective effects when given in eye drops, by increasing the traversing efficacy and enhancing the activation of the PAC1 receptor. Rats were subjected to bilateral carotid artery occlusion (BCCAO), and retinas were processed for histological analysis 14 days later. The efficiency of the TAT-bound peptides to reach the retina was assessed as well as their cAMP increasing ability. Our present study provides evidence, for the first time, that topically administered PACAP and VIP derivatives (PACAP-TAT and VIP-TAT) attenuate ischemic retinal degeneration via the PAC1 receptor presumably due to a multifactorial protective mechanism.

KW - Bio-barriers

KW - Eye drops

KW - Retinal protection

KW - TAT

UR - http://www.scopus.com/inward/record.url?scp=85058488859&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058488859&partnerID=8YFLogxK

U2 - 10.1007/s12031-018-1229-5

DO - 10.1007/s12031-018-1229-5

M3 - Article

AN - SCOPUS:85058488859

JO - Journal of Molecular Neuroscience

JF - Journal of Molecular Neuroscience

SN - 0895-8696

ER -